CoChat

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer

Open access
Si, Yiran, Yue, Jian, Liu, Zhaoyang, Li, Mo, Du, Feng, Wang, Xue, Dai, Zhong, Hu, Nanlin, Ju, Jie, Gao, Songlin, Wang, Xiaobing, Yuan, Peng · 2021 · International Journal of Nanomedicine

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Purpose: Immunologically quiescent of breast cancer cells has been recognized as the key impediment for the breast cancer immunotherapy. In this study, we aimed to investigate the role of nanoparticle-mediated sonodynamic therapy (SDT) in promoting anti-tumor immune of breast cancer cells and its potential immune mechanisms. Materials and Methods: The phase-transformation nanoparticles (LIP-PFH nanoparticles) were in-house prepared and its physiochemical characters were detected. The CCK-8 assay, apoptosis analysis and Balb/c tumor model establishment were used to explore the anti-tumor effect of LIP-PFH nanoparticles triggered by low-intensity focused ultrasound (LIFU) both in vitro and in vivo. Flow cytometry and immunohistochemistry of CD4 + T, CD8 + T, CD8 + PD-1 + T in blood, spleen and tumor tissue were performed to represent the change of immune response. Detection of immunogenic cell death (ICD) markers was examined to study the potential mechanisms. Results: LIP-PFH nanoparticles triggered by LIFU could inhibit the proliferation and promote the apoptosis of 4T1 cells both in vitro and in vivo. CD4 + T and CD8 + T cell subsets were significantly increased in blood, spleen and tumor tissue, meanwhile CD8 + PD-1 + T cells were reduced, indicating enhancement of anti-tumor immune response of breast cancer cells in the nanoparticle-mediated SDT group. Detection of ICD markers (ATP, high-mobility group box B1, and calreticulin) and flow cytometric analysis of dendritic cell (DC) maturity further showed that the nanoparticle-mediated SDT can promote DC maturation to increase the proportion of cytotoxic T cells by inducing ICD of breast cancer cells. Conclusion: The therapy of nanoparticles-mediated SDT can effectively enhance anti-tumor immune response of breast cancer. Keywords: breast cancer, immune response, phase-transformation nanoparticles, immunogenic cell death, DC maturation

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s297933

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Design of LIP-PFH nanoparticles and schematic illustration of phase-transition of LIP-PFH nanoparticles triggered by LIFU leading to cell damage in situ.
Figure 1 Design of LIP-PFH nanoparticles and schematic illustration of phase-transition of LIP-PFH nanoparticles triggered by LIFU leading to cell damage in situ.CC BY-NC · PubMed Central
Figure 2 Characteristics of LIP-PFH nanoparticles. (A) Visual appearance of prepared LIP-PFH nanoparticles; (B) OM images of LIP-PFH nanoparticles. Scale bar=5μm; (C) TEM images of LIP-PFH nanoparticles. Scale bar=500nm. (D) Size distribution of LIP-PFH nanoparticles. (E) The zeta potential of LIP-PFH nanoparticles.
Figure 2 Characteristics of LIP-PFH nanoparticles. (A) Visual appearance of prepared LIP-PFH nanoparticles; (B) OM images of LIP-PFH nanoparticles. Scale bar=5μm; (C) TEM images of LIP-PFH nanoparticles. Scale bar=500nm. (D) Size distribution of LIP-PFH nanoparticles. (E) The zeta potential of LIP-PFH nanoparticles.CC BY-NC · PubMed Central
Figure 3 Cellular uptake of LIP-PFH nanoparticles by 4T1 cells at continuously multiple time points. (A) Images of CLSM; (B) quantitative analysis of flow analysis.
Figure 3 Cellular uptake of LIP-PFH nanoparticles by 4T1 cells at continuously multiple time points. (A) Images of CLSM; (B) quantitative analysis of flow analysis.CC BY-NC · PubMed Central
Figure 4 Antitumor effect of LIP-PFH nanoparticles triggered by LIFU both in vitro and in vivo. (A) OM images and CLSM image of LIP-PFH nanoparticles before and after LIFU irradiation under different conditions (1W/m2, 1min, 2min, 3min); (B) cell proliferation assay of LIP-PFH nanoparticles incubated with 4T1 cells with LIFU irradiation (1W/m2, 2min); (C, D) flow analysis of apoptosis and the quantitative analysis of apoptosis; (E, F) cell cycle test for 4T1 cells with different intervention for 24h and the quantitative analysis of cells in the G0G1, S, and G2M phase, respectively; (G) schematic illustration of the in vivo experiment; (H) changes of tumor volume in each group over time (measured once every 3 days with a vernier caliper); (I) representative photographs of tumors (d28); (J) tumor weight in each group. n=6, *p<0.05, **p<0.01.
Figure 4 Antitumor effect of LIP-PFH nanoparticles triggered by LIFU both in vitro and in vivo. (A) OM images and CLSM image of LIP-PFH nanoparticles before and after LIFU irradiation under different conditions (1W/m2, 1min, 2min, 3min); (B) cell proliferation assay of LIP-PFH nanoparticles incubated with 4T1 cells with LIFU irradiation (1W/m2, 2min); (C, D) flow analysis of apoptosis and the quantitative analysis of apoptosis; (E, F) cell cycle test for 4T1 cells with different intervention for 24h and the quantitative analysis of cells in the G0G1, S, and G2M phase, respectively; (G) schematic illustration of the in vivo experiment; (H) changes of tumor volume in each group over time (measured once every 3 days with a vernier caliper); (I) representative photographs of tumors (d28); (J) tumor weight in each group. n=6, *p<0.05, **p<0.01.CC BY-NC · PubMed Central
Figure 5 LIP-PFH nanoparticles triggered by LIFU activated the immune response of T-cells in blood and spleen. (A–C) Dynamic changes of CD4+T, CD8+T and CD8+PD-1+T cells in the peripheral blood; (D) changes of IFN-γ released by peripheral blood; (E, F) the proportion of CD3+CD4+T and CD3+CD8+T cells in spleens; (G) the ratio of CD8+PD-1+T-cells in CD3+T cells; n=3, *p<0.05, **p<0.01, ***p<0.001.
Figure 5 LIP-PFH nanoparticles triggered by LIFU activated the immune response of T-cells in blood and spleen. (A–C) Dynamic changes of CD4+T, CD8+T and CD8+PD-1+T cells in the peripheral blood; (D) changes of IFN-γ released by peripheral blood; (E, F) the proportion of CD3+CD4+T and CD3+CD8+T cells in spleens; (G) the ratio of CD8+PD-1+T-cells in CD3+T cells; n=3, *p<0.05, **p<0.01, ***p<0.001.CC BY-NC · PubMed Central
Figure 6 Immune infiltration in tumor tissue. (A) H&E staining for pathological changes in tumor sections from each group. The black arrow represented cell necrosis, nuclear fragmentation or lysis. The red arrow represented lymphocytes infiltration; (B–D) representative images of immunochemistry staining for CD4, CD8 and PD-1 on T cells in different groups. Scale bar=100μm; (E) the statistical results of the IOD/Area of CD4 staining; (F) the statistical results of the IOD/Area of CD8 staining; (G) the statistical results of the IOD/Area of PD-1 staining; n=6, **p<0.01, ***p<0.001.
Figure 6 Immune infiltration in tumor tissue. (A) H&E staining for pathological changes in tumor sections from each group. The black arrow represented cell necrosis, nuclear fragmentation or lysis. The red arrow represented lymphocytes infiltration; (B–D) representative images of immunochemistry staining for CD4, CD8 and PD-1 on T cells in different groups. Scale bar=100μm; (E) the statistical results of the IOD/Area of CD4 staining; (F) the statistical results of the IOD/Area of CD8 staining; (G) the statistical results of the IOD/Area of PD-1 staining; n=6, **p<0.01, ***p<0.001.CC BY-NC · PubMed Central
Figure 7 LIP-PFH nanoparticles triggered by LIFU led to release of DAMPs to promote DC maturation. (A) Membrane exposure of CRT was analyzed by flow cytometry in uptake of LIP-PFH nanoparticles by 4T1 cells at 24h after LIFU stimulating. The mean fluorescence intensity (MFI) was calculated. (B) Extracellular release of ATP from 4T1 cells induced by LIP-PFH nanoparticles triggered by LIFU was measured at 3, 6, 12 and 24h, respectively. (C) HMGB1 released from 4T1 cells induced by LIP-PFH nanoparticles combined with LIFU was measured using ELISA kit, at 3, 6, 12 and 24h, respectively. (D–E) CRT and HMGB1 immunohistochemistry representative images and quantifications of CRT and HMGB1 positive area of tumors (IOD/area value), Scale bar=100μm, n=6; (F–H) representative flow cytometry images of mature DC (including surface markers CD80/MHCII/CD86+DC); (I) the proportion of CD11c+CD80+DC in spleens. (J) The proportion of CD11c+MHCII+DC in spleens; (K) the proportion of CD11c+CD86+DC cells in spleens; (L) the production of IFN-γ in peripheral blood determined by ELISA; n=3, **p<0.01, ***p<0.001.
Figure 7 LIP-PFH nanoparticles triggered by LIFU led to release of DAMPs to promote DC maturation. (A) Membrane exposure of CRT was analyzed by flow cytometry in uptake of LIP-PFH nanoparticles by 4T1 cells at 24h after LIFU stimulating. The mean fluorescence intensity (MFI) was calculated. (B) Extracellular release of ATP from 4T1 cells induced by LIP-PFH nanoparticles triggered by LIFU was measured at 3, 6, 12 and 24h, respectively. (C) HMGB1 released from 4T1 cells induced by LIP-PFH nanoparticles combined with LIFU was measured using ELISA kit, at 3, 6, 12 and 24h, respectively. (D–E) CRT and HMGB1 immunohistochemistry representative images and quantifications of CRT and HMGB1 positive area of tumors (IOD/area value), Scale bar=100μm, n=6; (F–H) representative flow cytometry images of mature DC (including surface markers CD80/MHCII/CD86+DC); (I) the proportion of CD11c+CD80+DC in spleens. (J) The proportion of CD11c+MHCII+DC in spleens; (K) the proportion of CD11c+CD86+DC cells in spleens; (L) the production of IFN-γ in peripheral blood determined by ELISA; n=3, **p<0.01, ***p<0.001.CC BY-NC · PubMed Central
Figure 8 Schematic diagram of the mechanism of the LIP-PFH nanoparticles triggered by LIFU to enhance anti-tumor immune.
Figure 8 Schematic diagram of the mechanism of the LIP-PFH nanoparticles triggered by LIFU to enhance anti-tumor immune.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 1

  1. Kuroki, 2007, Anticancer Res, 27, 3673

Cited by

See all 52

Metadata

Authors
Si, Y., Yue, J., Liu, Z., Li, M., Du, F., Wang, X., Dai, Z., Hu, N., Ju, J., Gao, S., Wang, X., & Yuan, P.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Peking University Cancer Hospital (CN)
  • Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Corresponding author
Yuan, Peng
Venue
International Journal of Nanomedicine
Published
2021-03
Volume
Volume 16
Pages
1913-1926
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
OpenAlex
W3134420868
Cited by
52
References
40
Citations by year
2026: 8 · 2025: 14 · 2024: 13 · 2023: 7 · 2022: 8 · 2021: 2
FWCI
2.28
Type
journal article
Language
en
Open access
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81672634)
  • Chinese Academy of Medical Sciences (12019XK320071)
  • Chinese Society of Clinical Oncology (Y-2019AZMS-0377)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
Keywords
sonodynamic therapy, low-intensity focused ultrasound, breast cancer, immunogenic cell death, antitumor immunity, dendritic cell maturation, CD8+ T cells, PD-1, apoptosis, 4T1 cells, calreticulin, HMGB1, cancer immunotherapy
MeSH terms
Immunogenic Cell Death, Animals, Dendritic Cells, Endocytosis, Female, Fluorocarbons, Immunity, Immunotherapy, Mice, Inbred BALB C, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Ultrasonic Therapy, Mammary Neoplasms, Animal, Apoptosis, Cell Line, Tumor, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.